Hepatitis Forums
Hepatitis C Main Forums => Hepatitis C Research News & Studies => Topic started by: Hep Editors on December 15, 2015, 02:10:39 pm
-
A new study published in JAMA Internal Medicine shows treating hepatitis C in individuals with genotype 1 of the virus—even when they have milder cases of liver fibrosis—is still more cost-effective than waiting until liver disease progresses.
That's a big deal, because treating even half of all eligible Americans with hep C genotype 1 (at current drug prices) would cost an estimated $53 billion.
For more information: http://www.hepmag.com/articles/cost_effectiveness_2501_28175.shtml